147 related articles for article (PubMed ID: 30662676)
1. Targeting TNFα in severe psoriasis-mass spectrometry reveals a time-dependent specific inhibition of Factor H in responding patients.
Morlière P; Antunes JF; Nourry V; Amado FM; Domingues PM; Guerreiro AC; Ferreira JA; Maia-Silva JN; Mazière JC; Santus RC; Filipe PL
Am J Transl Res; 2018; 10(12):4338-4349. PubMed ID: 30662676
[TBL] [Abstract][Full Text] [Related]
2. LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFα treatment.
Kamleh MA; Snowden SG; Grapov D; Blackburn GJ; Watson DG; Xu N; Ståhle M; Wheelock CE
J Proteome Res; 2015 Jan; 14(1):557-66. PubMed ID: 25361234
[TBL] [Abstract][Full Text] [Related]
3. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
4. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of glycation and glycation sites of lysozyme by matrix-assisted laser desorption/ionization time of flight/time-of-flight mass spectrometry and Liquid chromatography-electrospray ionization tandem mass spectrometry.
Ruan ED; Wang H; Ruan Y; Juáreza M
Eur J Mass Spectrom (Chichester); 2014; 20(4):327-36. PubMed ID: 25420345
[TBL] [Abstract][Full Text] [Related]
6. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
7. Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients.
Jin W; Zhang S; Duan Y
Dermatology; 2019; 235(1):55-64. PubMed ID: 30408786
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
[TBL] [Abstract][Full Text] [Related]
9. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
[TBL] [Abstract][Full Text] [Related]
10. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
[TBL] [Abstract][Full Text] [Related]
11. Matrix-assisted laser desorption/ionization directed nano-electrospray ionization tandem mass spectrometric analysis for protein identification.
Kast J; Parker CE; van der Drift K; Dial JM; Milgram SL; Wilm M; Howell M; Borchers CH
Rapid Commun Mass Spectrom; 2003; 17(16):1825-34. PubMed ID: 12876682
[TBL] [Abstract][Full Text] [Related]
12. High-resolution liquid chromatography/electrospray ionization time-of-flight mass spectrometry combined with liquid chromatography/electrospray ionization tandem mass spectrometry to identify polyphenols from grape antioxidant dietary fiber.
Touriño S; Fuguet E; Jáuregui O; Saura-Calixto F; Cascante M; Torres JL
Rapid Commun Mass Spectrom; 2008 Nov; 22(22):3489-500. PubMed ID: 18853405
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
[TBL] [Abstract][Full Text] [Related]
14. Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept.
Yang A; Xin X; Yang W; Li M; Yang W; Li L; Liu X
Ann Dermatol Venereol; 2019 May; 146(5):363-371. PubMed ID: 31047699
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study.
Xie F; Wang R; Zhao ZG; Meng XF; Lin BW; Yang J; Wang WJ; Ding XY; Yang Y; Zhao H; Li CX; Li HJ; Zhou Y
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):943-947. PubMed ID: 29270758
[TBL] [Abstract][Full Text] [Related]
16. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
17. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
Puig L; Dossenbach M; Berggren L; Ljungberg A; Zachariae C
Acta Derm Venereol; 2019 Oct; 99(11):971-977. PubMed ID: 31240322
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
19. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study.
de Vries AC; Thio HB; de Kort WJ; Opmeer BC; van der Stok HM; de Jong EM; Horvath B; Busschbach JJ; Nijsten TE; Spuls PI
Br J Dermatol; 2017 Mar; 176(3):624-633. PubMed ID: 27416891
[TBL] [Abstract][Full Text] [Related]
20. Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges.
Patel DN; Li L; Kee CL; Ge X; Low MY; Koh HL
J Pharm Biomed Anal; 2014 Jan; 87():176-90. PubMed ID: 23721687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
